A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs DP 001 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacodynamics
- Sponsors Deltanoid Pharmaceuticals
- 13 Sep 2017 Results published in the Drugs in R and D
- 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2014 Planned End Date changed from 1 Apr 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.